NCT04182932Unknown1 期
A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Frequency and severity of adverse events of CJ-40010 (Safety of CJ-40010)
研究概览
简要总结
This study aims to evaluate the safety and immunogenicity of CJ-40010 after administration in healthy subjects
详细描述
Enterovirus 71(EV71) and coxsackievirus A16(CVA16) are major causes of Hand-foot-and-mouth disease (HFMD) occurring in pediatric population. Although EV71 vaccine has been licensed in China, vaccine for CVA16-associated HFMD is currently not available anywhere. The purpose of this phase I study is to evaluate the safety and immunogenicity of EV71/CVA16 bivalent vaccine in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult men and women aged ≥19 to <50 years at the time of screening tests
- •Body mass index(BMI)* of ≥18.0 kg/m2 to ≤27.0 kg/m2, with body weight of ≥55.0 kg to ≤90.0 kg for men and ≥50.0 kg to ≤90.0 kg for women at the time of screening tests
- •*BMI (kg/m2) = Body weight (kg) / {height (m)}2
- •Determined by the investigator to be eligible for study participation based on the results of screening tests (medical examination by interview, physical examination, vital signs, ECG, and clinical laboratory tests) conducted within 4 weeks of the 1st IP administration
- •Intact deltoid muscle* that allows administration of the investigational product
- •*Those who have a wound, scar, tattoo, skin disorder or infection on the expected investigational product administration site (deltoid muscle) that can affect safety evaluation cannot enter the study
- •Consent to use medically acceptable contraception* throughout the study
- •*Medically acceptable contraception: Use of an intrauterine device with a demonstrated pregnancy failure rate, concurrent use of a barrier method (male or female) and spermicide, surgical contraception of the subject or partner (vasectomy, salpingectomy/tubal ligation, hysterectomy, bilateral oophorectomy)
- •Negative finding from a pregnancy test (urine hCG) at the time of the screening visit, after using medically acceptable contraception prior to 30 days of screening for women of childbearing potential*
- •*Women of childbearing potential: Women who have not passed 1 year after menopause or not surgically sterilized (hysterectomy, bilateral oophorectomy)
- •Voluntary decision and provision of written consent on participation in this study
排除标准
- •History of a hand-foot-mouth disease or history of a disease related with enterovirus(EV) infection such as herpangina, viral meningitis, encephalitis, acute hemorrhagic conjunctivitis or myocarditis within 3 months prior to the 1st IP administration
- •Medical history of an anaphylactic or similar acute reaction to CJ-40010 or similar vaccine
- •Febrile disease or infectious disease within 2 weeks prior to the 1st IP administration
- •Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP administration
- •Vaccination with other prevention vaccine within 2 months prior to the 1st IP administration
- •Use of an immunomodulator or immunosuppressant* within 3 months prior to the 1st IP administration
- •e.g., Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus
- •High dose corticosteroids (continuous use for 14 days or more at ≥20 mg/day for Prednisolone. However, use of inhaled, intranasal or topical corticosteroids is allowed irrespective of the administered dose).
- •History of a Guillain Barre syndrome
- •Excessive caffeine intake (>5 units/day) or continuous alcohol consumption (>21 units/week, 1 unit = 10 g of pure alcohol) or incapable of abstention from alcohol during the study
- •Participation in other clinical trial within 6 months prior to the 1st IP administration
- •Pregnant or breastfeeding women
- •Clinically significant hepatic, renal, neurological, respiratory, endocrine, hematology and oncology, cardiovascular, urological or psychiatric disease or such history
- •Positive serological finding (type B hepatitis test, type C hepatitis test, human immunodeficiency virus(HIV) test)
- •History of drug abuse or positive finding from a urine screening test for an abusive drug
- •Use or of any prescription medication or oriental medicine within 2 weeks or any over-the-counter(OTC) medication, health functional food or vitamin within 1 week prior to the 1st IP administration (however, those who administered an allowed drug as specified in the other exclusion criterion can enter the study) or expected use of such products
- •Administration of a blood product or blood-derived agent within 3 months prior to the 1st IP administration
- •Determined by the investigator to be ineligible for study participation due to other reason including clinical laboratory findings
结局指标
主要结局
Frequency and severity of adverse events of CJ-40010 (Safety of CJ-40010)
时间窗: Week 0 to Week 32
- Frequency and severity of adverse events up to 32 weeks post first dose
次要结局
- Immunogenicity of CJ-40010 : Geometric mean titer (GMT) of EV71 neutralizing antibody titers(Week 0 to Week 32)
- Immunogenicity of CJ-40010 : Anti-EV71 IgG titer(Week 0 to Week 32)
- Immunogenicity of CJ-40010 : Anti-CVA16 IgG titer(Week 0 to Week 32)
- Immunogenicity of CJ-40010 : GMT of CVA16 neutralizing antibody titers(Week 0 to Week 32)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory AllergiesMild Asthma and Allergic RhinitisNCT01788813GlaxoSmithKline42
已完成
1 期
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian ParticipantsHealthy VolunteersNCT06148181AbbVie41
已完成
1 期
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)PostmenopausalOsteopeniaNCT01825785Amgen48
终止
1 期
A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401Healthy VolunteersNCT01627002ProtAffin Biotechnologie AG49
已完成
1 期
Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV VaccineHIV InfectionNCT00482027International AIDS Vaccine Initiative80